Jacobs Levy Equity Management
TNGX icon

Jacobs Levy Equity Management’s Tango Therapeutics TNGX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-218,779
Closed -$1.12M – 1116
2025
Q2 		$1.12M Sell
218,779
-519,176
-70% -$1.28M ﹤0.01% 737
2025
Q1 		$1.01M Buy
737,955
+220,529
+43% +$542K ﹤0.01% 807
2024
Q4 		$1.6M Buy
+517,426
New +$2.4M 0.01% 642
2024
Q2 		– Sell
-21,338
Closed -$169K – 1041
2024
Q1 		$169K Sell
21,338
-34,476
-62% -$370K ﹤0.01% 900
2023
Q4 		$553K Sell
55,814
-87,667
-61% -$761K ﹤0.01% 815
2023
Q3 		$1.62M Sell
143,481
-175,295
-55% -$1.07M 0.01% 598
2023
Q2 		$1.06M Sell
318,776
-86,789
-21% -$312K 0.01% 691
2023
Q1 		$1.6M Buy
405,565
+59,094
+17% +$343K 0.01% 613
2022
Q4 		$2.51M Buy
346,471
+548
+0.2% +$3.85K 0.02% 510
2022
Q3 		$1.25M Buy
+345,923
New +$1.48M 0.01% 660

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's TNGX Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Tango Therapeutics (TNGX) in Q3 2025, closing a stake of 218,779 shares — an estimated $1.12M sold.

Jacobs Levy Equity Management first reported a position in TNGX in Q3 2022 and held it in 10 quarters. The position peaked at $2.51M in Q4 2022. 141 funds tracked by Wall St. Rank hold TNGX as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Tango Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 218,779 Tango Therapeutics shares in Q3 2025, an estimated $1.12M.
  • Jacobs Levy Equity Management first reported a position in Tango Therapeutics in Q3 2022 and held it in 10 quarters.
  • Jacobs Levy Equity Management's Tango Therapeutics position peaked at $2.51M in Q4 2022.
  • 141 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.